Home Latest Articles
Latest Articles
  • Jiao YIN, Ying WANG, Shantang YANG, Fei LI, Jun HU, Pengliang HAO
    Chinese Journal of Pharmaceuticals. 2026, 57(9): 1105-1110.

    This study performed environmental monitoring and microbial identification in 23 “controlled not classified”(CNC) areas of a sterile pharmaceutical production workshop from 2024 to 2025. The results indicated significant differences in contamination load and microbial community structure across different functional areas: the changing area had the highest level of contamination with a microbial proportion of 43.75%, followed by the personnel flow area(33.48%), the cleaning area(10.03%), the logistics area(8.92%), and the waste logistics area(3.82%). The microorganisms isolated across all CNC areas were classified into 10 bacterial genera, with Staphylococcus being the most prevalent(32.14%), followed by Bacillus(17.86%), Candida(14.29%), and Micrococcus(10.71%). A baseline database of contaminating microorganisms in CNC areas of the sterile pharmaceutical manufacturing workshop was established,providing data support and scientific evidence for optimizing environmental control, cleaning and disinfection, microbial contamination traceability, and formulating cleanliness standards by pharmaceutical regulatory authorities.

  • Xinyue ZOU, Xiyuchen YANG, Yunong DAI, Xinyi SUN
    Chinese Journal of Pharmaceuticals. 2026, 57(9): 1111-1115.

    An ICP-MS method was established for the simultaneous determination of 12 types of elemental impurities including cadmium, lead, arsenic, mercury, cobalt, vanadium, nickel, lithium, antimony, molybdenum, copper, chromium in semaglutide bulk drug. The samples were digested by microwave-assisted digestion after addition of nitric acid, and the contents of the 12 elemental impurities in semaglutide bulk drug were simultaneously quantified using the internal standard method. The results showed that each elemental impurity had a good linear relationship between the mass concentration and response signal within its respective range(r>0.999 2), with LODs of 0.000 3 - 0.045 1 μg/g, and LOQs of 0.001 0 -0.136 6 μg/g. The spike recoveries were in the range of 86.3% - 124.6%. The RSDs of repeatability test(n=6) were 0.33% -4.24%. The RSDs of intermediate precision test(n=12) were 0.90% - 6.27%. Three batches of samples were detected by this method, and all elemental impurity levels complied with the specified limits. The method established herein features high sensitivity and acceptable accuracy, and can be applied to the quality control of elemental impurities in semaglutide.

  • Hui LI, Songyue ZHAO, Qin XU, Hongsheng HAN
    Chinese Journal of Pharmaceuticals. 2026, 57(9): 1116-1120.
  • Haibing YIN, Wenjun FU, Jinfang ZHAO, Xiaonan LIU, Yongze WANG
    Chinese Journal of Pharmaceuticals. 2026, 57(9): 1121-1126.
  • Jiaji WANG, Xing CHENG, Lijia GUI, Wenwu GONG
    Chinese Journal of Pharmaceuticals. 2026, 57(9): 1127-1131.
  • Wenxia ZHANG, Xueke MENG, Rui HUANG, Gang FENG, Zhuo LI
    Chinese Journal of Pharmaceuticals. 2026, 57(9): 1132-1136.
  • Zhongpeng WANG, Meng REN
    Chinese Journal of Pharmaceuticals. 2026, 57(9): 1137-1140.
  • Wenjing YAN, Weigen LU, Xiaohong LU, Jun HE
    Chinese Journal of Pharmaceuticals. 2026, 57(8): 877-885.

    The onset and progression of liver diseases are generally accompanied by immune-inflammatory dysregulation. Hepatic macrophages play a central role in amplifying pro-inflammatory responses, regulating oxidative stress, promoting fibrotic remodeling, and shaping the tumor immune microenvironment, rendering them important targets for precision therapy in liver diseases. In recent years, drug delivery systems targeting hepatic macrophages have been continuously developed, with strategies expanding from passive accumulation strategies to multi-tiered systems featuring ligand recognition, microenvironment-responsive delivery, biomimetic camouflage, and in situ cellular reprogramming. From the perspective of drug delivery, this review summarizes representative strategies,including lipid nanoparticles, polymeric and stimuli-responsive systems, inorganic/hybrid nanomaterials, extracellular vesicles, and cell membrane-biomimetic systems, with a focus on analyzing their applicability and limitations in different pathological contexts, such as acute liver injury, metabolic liver disease, liver fibrosis, and hepatocellular carcinoma. Furthermore, key issues including hepatic macrophage subset heterogeneity, intracellular delivery efficiency, long-term safety, and industrial feasibility are discussed, along with a clinical translation prospect in this field, aiming to provide a reference for precision therapy of liver diseases.

  • Hong WANG, Jiajing WANG, Xiaojuan HU, Kuaile LIN, Yifei CHEN
    Chinese Journal of Pharmaceuticals. 2026, 57(8): 886-892.

    Microfluidic technology involves continuous-flow chemical reactions and separations in micro-devices with critical dimensions ranging from micrometers to sub-millimeter scales. In recent years, microfluidic technology has evolved rapidly from initial concept to industrial-scale applications. The microfluidic reactor, serving as the core platform and a key device for microfluidic technology, offers advantages including excellent mass- and heat-transfer performance,high safety, precise controllability, and ease of scale-up. These advantages have driven rapid development of microfluidic technology applications in the pharmaceutical field, with representative scenarios including drug synthesis and the preparation of nanoformulations. This review briefly introduces the structure of microfluidic technology, with a focus on its pharmaceutical applications and technical considerations for production-scale implementations.

  • Wancheng ZHOU, Haibo PAN, Ke HE, Han BAO, Pengcheng QIU
    Chinese Journal of Pharmaceuticals. 2026, 57(8): 893-904.

    To control the quality of daridorexant hydrochloride(1), a dual orexin receptor antagonist,investigations on the impurities of intermediates and API were carried out in this study. An intermediate impurity was identified as 2-hydroxy-5-methoxybenzoic acid(13) by comparison with a reference standard. A series of impurities were synthesized, including two difficult-to-remove intermediate impurities, namely 5-methoxy-N,N-dimethyl-2-(2H-1,2,3-triazol-2-yl)benzamide(16) and (S)-1-[5-methoxy-2-(2H-1,2,3-triazol-2-yl)benzoyl]-N,N,2-trimethylpyrrolidine-2-carboxamide(24). Four API impurities were also identified, including (S)-[2-(5-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl][5-methoxy-2-(1H-1,2,3-triazol-1-yl)phenyl]methanone hydrochloride(25), (S)-(2-bromo-5-methoxyphenyl)[2-(5-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl]methanone hydrochloride(26), (R)-[2-(5-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl][5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone hydrochloride(27), and (S)-[5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl][2-methyl-2-(4-methyl-1H-benzo[d]imidazol-2-yl)pyrrolidin-1-yl]methanone hydrochloride(29). In addition, two degradation impurities were isolated, including 5-methoxy-2-(2H-1,2,3-triazol-2-yl)benzoic acid(4) and (S)-5-chloro-4-methyl-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole(30). The synthesis and structural characterization of impurities 16, 24, 25,26, 27 and 29 were reported for the first time in this work. The degradation behavior of compound 1 under high-temperature alkaline conditions was revealed. By controlling parameters such as water content, temperature and reaction time, together with recrystallization or washing operations,the contents of the above-mentioned impurities in the final product can be controlled below 0.1%.

News